Trial Profile

Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary)
Indications Bacteraemia; Endocarditis; Gram-positive infections; Osteomyelitis
Focus Adverse reactions; Therapeutic Use
Acronyms SUDDEN-OUT

Most Recent Events

17 Oct 2023 Status changed from recruiting to discontinued.
04 May 2021 Planned End Date changed from 18 Apr 2024 to 29 Apr 2024.
04 May 2021 Planned primary completion date changed from 18 Apr 2024 to 29 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com